<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mrj</journal-id><journal-title-group><journal-title xml:lang="ru">Современная ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Modern Rheumatology Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1996-7012</issn><issn pub-type="epub">2310-158X</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1996-7012-2010-625</article-id><article-id custom-type="elpub" pub-id-type="custom">mrj-310</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Лечение бисфосфонатами и патология пищевода</article-title><trans-title-group xml:lang="en"><trans-title>BISPHOSPHONATE TREATMENT AND ESOPHAGEAL DISEASE</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Karateyev</surname><given-names>Andrei Evgenyevich</given-names></name><name name-style="western" xml:lang="en"><surname>Karateyev</surname><given-names>Andrei Evgenyevich</given-names></name></name-alternatives><email xlink:type="simple">aekarateev@rambler.ru &amp;lt;mailto:aekarateev@rambler.ru&amp;gt;</email></contrib></contrib-group><pub-date pub-type="collection"><year>2010</year></pub-date><pub-date pub-type="epub"><day>11</day><month>09</month><year>2010</year></pub-date><volume>4</volume><issue>3</issue><issue-title>№3 (2010)</issue-title><fpage>73</fpage><lpage>79</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Karateyev A.E., 2010</copyright-statement><copyright-year>2010</copyright-year><copyright-holder xml:lang="ru">Karateyev A.E.</copyright-holder><copyright-holder xml:lang="en">Karateyev A.E.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://mrj.ima-press.net/mrj/article/view/310">https://mrj.ima-press.net/mrj/article/view/310</self-uri><abstract><p>Обсуждается проблема побочных эффектов при использовании бисфосфонатов. Отмечено, что существенное значение для реальной клинической практики имеют осложнения со стороны желудочно-кишечного тракта, которые наблюдаются у 20-30% пациентов и являются основной причиной отказа от лечения. Этот аспект переносимости бисфосфонатов тщательно изучается, поскольку, помимо неспецифических симптомов (диспепсия или гастралгия), некоторые представители этой лекарственной группы способны вызывать и весьма серьезные специфические осложнения - язвы пищевода. Значительно уменьшить риск подобных осложнений, по-видимому, помогут использование новых препаратов и лекарственных форм, а также тщательный учет факторов риска при их назначении, четкие инструкции по применению и своевременный контроль за состоянием больных.</p></abstract><trans-abstract xml:lang="en"><p>The problem of adverse reactions caused by the use of bisphosphonate is discussed. Gastrointestinal reactions that are observed in 20-30% of patients and a main reason for refusal to be treated are noted to be of considerable importance for real clinical practice. This aspect of bisphosphonate intolerability is being thoroughly investigated since some representatives of this drug group are able to induce very serious specific complications, such as esophageal ulcers, in addition to nonspecific symptoms (dyspepsia or gastralgia). The administration of novel drugs and formulations, careful consideration of risk factors in their prescription, clear use instructions, and timely monitoring the patients' status seem to assist in substantially reducing the risk of such reactions.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>гастродуоденальная патология</kwd><kwd>бисфосфонаты</kwd><kwd>алендронат</kwd><kwd>ибандронат</kwd></kwd-group><kwd-group xml:lang="en"><kwd>gastroduodenal pathology</kwd><kwd>bisphosphonates</kwd><kwd>alendronate</kwd><kwd>ibandronate</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
